Pub Date : 2023-10-03DOI: 10.24875/recice.m23000401
José F. Díaz Fernández
{"title":"Debate. Percutaneous revascularization in dilated cardiomyopathy. Apropos of the REVIVED BCIS2 trial: the interventional cardiologist�s view","authors":"José F. Díaz Fernández","doi":"10.24875/recice.m23000401","DOIUrl":"https://doi.org/10.24875/recice.m23000401","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135689406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-05DOI: 10.24875/recice.m23000408
José Miguel Viegas, Ruben Ramos, A. Fiarresga, L. Sousa, Duarte Cacela and, R. Cruz Ferreira
Treatment failure is a major concern after full metal jacket (FMJ) stenting procedures, defined as overlapping stent length ≥ 60 mm. These procedures are often required to treat tandem or extensive coronary lesions.1 Several brands of stents are currently approved, each displaying different characteristics and performance. However, real-world practice is not restricted to the use of a brand exclusive strategy and may involve a combination of different brands. Limited data exist on the relative safety and efficacy of these different strategies during percutaneous coronary intervention (PCI). Therefore, our aim was to compare clinical outcomes after the use of a single stent brand vs multiple stent brands following successful FMJ PCI.
{"title":"Comparison of long-term outcomes between a single versus a multiple stent brand strategy during �full metal jacket� procedures","authors":"José Miguel Viegas, Ruben Ramos, A. Fiarresga, L. Sousa, Duarte Cacela and, R. Cruz Ferreira","doi":"10.24875/recice.m23000408","DOIUrl":"https://doi.org/10.24875/recice.m23000408","url":null,"abstract":"Treatment failure is a major concern after full metal jacket (FMJ) stenting procedures, defined as overlapping stent length ≥ 60 mm. These procedures are often required to treat tandem or extensive coronary lesions.1 Several brands of stents are currently approved, each displaying different characteristics and performance. However, real-world practice is not restricted to the use of a brand exclusive strategy and may involve a combination of different brands. Limited data exist on the relative safety and efficacy of these different strategies during percutaneous coronary intervention (PCI). Therefore, our aim was to compare clinical outcomes after the use of a single stent brand vs multiple stent brands following successful FMJ PCI.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46382354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-05DOI: 10.24875/recice.m23000398
S. López-Tejero, Pablo Antúnez-Muiños, Gilles Barreira-de Sousa, Alejandro Diego-Nieto, Javier Martín-Moreiras, and, Ignacio Cruz-González
{"title":"�Tailored TAVI�: the importance of the deployment mechanism","authors":"S. López-Tejero, Pablo Antúnez-Muiños, Gilles Barreira-de Sousa, Alejandro Diego-Nieto, Javier Martín-Moreiras, and, Ignacio Cruz-González","doi":"10.24875/recice.m23000398","DOIUrl":"https://doi.org/10.24875/recice.m23000398","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49649828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-05DOI: 10.24875/recice.m23000406
Diana Isabel Katekaru-Tokeshi, Haydi Andrea Ale-Gonzáles, Piero Custodio-Sánchez, Moisés Jiménez-Santos, Eric Kimura-Hayama and, Francisco Castillo-Castellón
This retrospective analytical study included symptomatic patients with severe aortic stenosis referred for multidetector computed tomography as part of the TAVI protocol from December 2012 through October 2022. Written informed consent was obtained from all patients prior to the tomography scan. We excluded patients with bicuspid aortic valve anatomy, pacemaker carriers, and those with biological bioprosthetic valves. The aim of this study was to determine whether MS length is associated with the need for pacemaker implantation after TAVI. MS length was measured as the maximum distance from the plane of the aortic annulus to the top of the muscular portion of the ventricular septum in the coronal plane during systole (figure 1A,B).2 Qualitative variables were analyzed using the chi-square test or Fisher exact test, while quantitative variables were analyzed using the Mann-Whitney U test. P values < .005 were considered statistically significant. A receiver operating characteristic (ROC) curve was constructed to assess the predictive accuracy of MS length for pacemaker implantation. Data were analyzed using the IBM SPSS statistical software package, version 26 (United States).
{"title":"Relationship between membranous septum length and need for pacemaker implantation after transcatheter aortic valve implantation","authors":"Diana Isabel Katekaru-Tokeshi, Haydi Andrea Ale-Gonzáles, Piero Custodio-Sánchez, Moisés Jiménez-Santos, Eric Kimura-Hayama and, Francisco Castillo-Castellón","doi":"10.24875/recice.m23000406","DOIUrl":"https://doi.org/10.24875/recice.m23000406","url":null,"abstract":"This retrospective analytical study included symptomatic patients with severe aortic stenosis referred for multidetector computed tomography as part of the TAVI protocol from December 2012 through October 2022. Written informed consent was obtained from all patients prior to the tomography scan. We excluded patients with bicuspid aortic valve anatomy, pacemaker carriers, and those with biological bioprosthetic valves. The aim of this study was to determine whether MS length is associated with the need for pacemaker implantation after TAVI. MS length was measured as the maximum distance from the plane of the aortic annulus to the top of the muscular portion of the ventricular septum in the coronal plane during systole (figure 1A,B).2 Qualitative variables were analyzed using the chi-square test or Fisher exact test, while quantitative variables were analyzed using the Mann-Whitney U test. P values < .005 were considered statistically significant. A receiver operating characteristic (ROC) curve was constructed to assess the predictive accuracy of MS length for pacemaker implantation. Data were analyzed using the IBM SPSS statistical software package, version 26 (United States).","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41943063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-31DOI: 10.24875/recice.m23000400
E. Spitzer
Cardialysis was founded in 1983 by visionary professionals from the Thoraxcenter at Erasmus University Medical Center (EMC) in Rotterdam, The Netherlands. This initiative emerged to address the need for a specialized research organization able to plan, execute, and report European cooperative clinical investigations in the field of cardiovascular research.1 The mission of Cardialysis is “to be at the heart of cardiovascular research” in the fullest sense of the phrase. To achieve this mission, the organization strives to collaborate with clinicians, trialists, research professionals, regulators, industry partners, and research organizations that share the same passion. Throughout the first 40 years, its well-established reputation has been based on dedication, diligence, and industry-leading standards. This has been made possible by attracting and retaining talented employees, as well as by cultivating long-standing relationships with investigators, clients, and partners.
{"title":"Forty years of Cardialysis: a leading European cardiovascular research organization","authors":"E. Spitzer","doi":"10.24875/recice.m23000400","DOIUrl":"https://doi.org/10.24875/recice.m23000400","url":null,"abstract":"Cardialysis was founded in 1983 by visionary professionals from the Thoraxcenter at Erasmus University Medical Center (EMC) in Rotterdam, The Netherlands. This initiative emerged to address the need for a specialized research organization able to plan, execute, and report European cooperative clinical investigations in the field of cardiovascular research.1 The mission of Cardialysis is “to be at the heart of cardiovascular research” in the fullest sense of the phrase. To achieve this mission, the organization strives to collaborate with clinicians, trialists, research professionals, regulators, industry partners, and research organizations that share the same passion. Throughout the first 40 years, its well-established reputation has been based on dedication, diligence, and industry-leading standards. This has been made possible by attracting and retaining talented employees, as well as by cultivating long-standing relationships with investigators, clients, and partners.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42085749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-17DOI: 10.24875/recice.m23000397
Asad Shabbir, D. Chipayo, A. Jerónimo, A. Travieso, N. Gonzalo, and Javier Escaned
Treatment of heavily calcified coronary artery disease (CAD) remains a technical challenge since a significant number of patients require some type or form of advanced plaque modification procedure in the cath lab. Therefore, interventional cardiologists should be aware of the complete array of plaque modification techniques available to prepare vessels to facilitate optimal stent deployment and expansion.1 In the presence of proximal calcified disease in tortuous vessels, orbital atherectomy can be used as an alternative to rotational atherectomy thanks to its greater stability with reverse ablation, improved ease of use, and convenience as a result of a single-size burr that can be used to treat a wide range of vessel profiles. In addition, it appears to have a similar safety profile compared to rotational atherectomy.2 We herein describe a case of 3-vessel proximal heavily calcified CAD where we demonstrate the feasibility of using orbital atherectomy to prepare all 3 epicardial vessels using a one-size burr guided by co-registered intravascular ultrasound (IVUS) and physiology prior to complete percutaneous revascularization in a single-staged procedure.
{"title":"Co-registration assisted 3-vessel orbital atherectomy in de novo calcified multivessel coronary artery disease","authors":"Asad Shabbir, D. Chipayo, A. Jerónimo, A. Travieso, N. Gonzalo, and Javier Escaned","doi":"10.24875/recice.m23000397","DOIUrl":"https://doi.org/10.24875/recice.m23000397","url":null,"abstract":"Treatment of heavily calcified coronary artery disease (CAD) remains a technical challenge since a significant number of patients require some type or form of advanced plaque modification procedure in the cath lab. Therefore, interventional cardiologists should be aware of the complete array of plaque modification techniques available to prepare vessels to facilitate optimal stent deployment and expansion.1 In the presence of proximal calcified disease in tortuous vessels, orbital atherectomy can be used as an alternative to rotational atherectomy thanks to its greater stability with reverse ablation, improved ease of use, and convenience as a result of a single-size burr that can be used to treat a wide range of vessel profiles. In addition, it appears to have a similar safety profile compared to rotational atherectomy.2 We herein describe a case of 3-vessel proximal heavily calcified CAD where we demonstrate the feasibility of using orbital atherectomy to prepare all 3 epicardial vessels using a one-size burr guided by co-registered intravascular ultrasound (IVUS) and physiology prior to complete percutaneous revascularization in a single-staged procedure.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43161636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-12DOI: 10.24875/recice.m23000394
A. Mendoza Soto, Leticia Albert de la Torre, Marta Flores Fernández, Dolores Herrera Linde, B. Toral Vázquez, and Ana Caro Barri
{"title":"Interventional catheterization in pediatric patients after Fontan procedure","authors":"A. Mendoza Soto, Leticia Albert de la Torre, Marta Flores Fernández, Dolores Herrera Linde, B. Toral Vázquez, and Ana Caro Barri","doi":"10.24875/recice.m23000394","DOIUrl":"https://doi.org/10.24875/recice.m23000394","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46639663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-10DOI: 10.24875/recice.m23000386
J. López-Mínguez, E. Suárez-Corchuelo, S. López-Tejero, L. Nombela‐Franco, X. Freixa-Rofastes, G. Bastos-Fernandez, X. Millán-Álvarez, R. Moreno-Gómez, J. Fernandez-Diaz, I. Amat-Santos, T. Benito-González, F. Alfonso-Manterola, P. Salinas-Sanguino, P. Cepas-Guillen, D. Arzamendi, I. Cruz-González, and Juan Manuel Nogales-Asensio
Introduction and objectives: The treatment of patients with non-valvular atrial fibrillation (NVAF) who need coronary stenting is challenging. The objective of the study was to determine whether left atrial appendage occlusion (LAAO) could be a feasible option and benefit these patients. To this end, we studied the impact of LAAO plus antiplatelet drugs vs oral anticoagulants (OAC) (including direct OAC) plus antiplatelet drugs in these patients’ long-term outcomes . Methods: The results of 207 consecutive patients with NVAF who underwent coronary stenting were analyzed. A total of 146 patients were treated with OAC (75 with acenocoumarol, 71 with direct OAC) while 61 underwent LAAO. The median follow-up was 35 months. Patients also received antiplatelet therapy as prescribed by their cardiologist. The study received the proper ethical oversight. Results: Age (mean 75.7 years), and the past medical history of stroke were similar in both groups. However, the LAAO group had more unfavorable characteristics (history of coronary artery disease [CHA 2 DS 2 -VASc], and significant bleeding [BARC ≥ 2] and HAS-BLED). The occurrence of major adverse events (death, stroke/transient ischemic events, major bleeding) and major cardiovascular events (cardiac death, stroke/transient ischemic attack, and myocardial infarction) were significantly higher in the OAC group compared to the LAAO group: 19.75% vs 9.06% (HR, 2.18; P = .008) and 6.37% vs 1.91% (HR, 3.34; P = .037), respectively. Conclusions: In patients with NVAF undergoing coronary stenting, LAAO plus antiplatelet therapy produced better long-term outcomes compared to treatment with OAC plus antiplatelet therapy despite the unfavorable baseline characteristics of the LAAO group.
{"title":"Left atrial appendage occlusion vs oral anticoagulants in atrial fibrillation and coronary stenting. The DESAFIO registry","authors":"J. López-Mínguez, E. Suárez-Corchuelo, S. López-Tejero, L. Nombela‐Franco, X. Freixa-Rofastes, G. Bastos-Fernandez, X. Millán-Álvarez, R. Moreno-Gómez, J. Fernandez-Diaz, I. Amat-Santos, T. Benito-González, F. Alfonso-Manterola, P. Salinas-Sanguino, P. Cepas-Guillen, D. Arzamendi, I. Cruz-González, and Juan Manuel Nogales-Asensio","doi":"10.24875/recice.m23000386","DOIUrl":"https://doi.org/10.24875/recice.m23000386","url":null,"abstract":"Introduction and objectives: The treatment of patients with non-valvular atrial fibrillation (NVAF) who need coronary stenting is challenging. The objective of the study was to determine whether left atrial appendage occlusion (LAAO) could be a feasible option and benefit these patients. To this end, we studied the impact of LAAO plus antiplatelet drugs vs oral anticoagulants (OAC) (including direct OAC) plus antiplatelet drugs in these patients’ long-term outcomes . Methods: The results of 207 consecutive patients with NVAF who underwent coronary stenting were analyzed. A total of 146 patients were treated with OAC (75 with acenocoumarol, 71 with direct OAC) while 61 underwent LAAO. The median follow-up was 35 months. Patients also received antiplatelet therapy as prescribed by their cardiologist. The study received the proper ethical oversight. Results: Age (mean 75.7 years), and the past medical history of stroke were similar in both groups. However, the LAAO group had more unfavorable characteristics (history of coronary artery disease [CHA 2 DS 2 -VASc], and significant bleeding [BARC ≥ 2] and HAS-BLED). The occurrence of major adverse events (death, stroke/transient ischemic events, major bleeding) and major cardiovascular events (cardiac death, stroke/transient ischemic attack, and myocardial infarction) were significantly higher in the OAC group compared to the LAAO group: 19.75% vs 9.06% (HR, 2.18; P = .008) and 6.37% vs 1.91% (HR, 3.34; P = .037), respectively. Conclusions: In patients with NVAF undergoing coronary stenting, LAAO plus antiplatelet therapy produced better long-term outcomes compared to treatment with OAC plus antiplatelet therapy despite the unfavorable baseline characteristics of the LAAO group.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44528678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：